Boston Scientific reports steady Q1 2026 performance yet tempers FY26 outlook
Summary
Despite Boston’s Q1 performance denoting a YoY rise of 11.2%, the company has trimmed its full-year growth outlook by 2% at the top-end.
Description
Despite Boston’s Q1 performance denoting a YoY rise of 11.2%, the company has trimmed its full-year growth outlook by 2% at the top-end.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source